Key terms
About PCSA
Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its main product candidate is PCS499, which is intended for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on March 29, 2011 and is headquartered in Hanover, MD.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest PCSA news
Apr 11
8:13am ET
Processa presents two abstracts at AACR 2024 including data on NGC-Cap trial
Mar 31
2:02am ET
Processa Pharmaceuticals’ Future in Jeopardy: A Dive into Its Financial Crisis and Industry Risks
Feb 07
4:15am ET
Processa Pharmaceuticals Secures NASDAQ Listing Compliance
Feb 06
8:45am ET
Processa Pharmaceuticals regains compliance with Nasdaq minimum bid price rule
Jan 26
12:25pm ET
Processa Pharmaceuticals (PCSA) Gets a Hold from Maxim Group
Jan 26
9:08am ET
Processa Pharmaceuticals prices 1.56M shares at $4.50 in public offering
Jan 26
4:15am ET
Processa Pharmaceuticals Completes Phase 1b Safety Evaluation
Jan 25
8:40am ET
Processa Pharmaceuticals announces successful completion of Phase 1b trial
Jan 20
3:05am ET
Processa Pharmaceuticals Expands NGC-Cap Cancer Program
Jan 19
7:50pm ET
Processa Pharmaceuticals Inc trading halted, news pending
Jan 19
7:46am ET
Processa expands NGC-Cap program into advanced or metastatic breast cancer
Jan 18
7:46am ET
Processa Pharmaceuticals to effect 1-for-20 reverse stock split
No recent press releases are available for PCSA
PCSA Financials
Key terms
Ad Feedback
PCSA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
PCSA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
